Related Experiment Videos
Pain management, including intrathecal pumps.
Thomas J Smith1, Craig Swainey, Patrick J Coyne
1Division of Hematology/Oncology and Palliative Care, Massey Cancer Center of Virginia Commonwealth University, MCV Box 980230, Richmond, VA 23298-0230, USA. tsmith@hsc.vcu.edu
Current Pain and Headache Reports
|July 12, 2005
Summary
Implantable drug delivery systems (IDDS) offer superior pain relief and reduced side effects for cancer patients compared to standard care. This approach significantly improves outcomes for even the most challenging pain cases.
Area of Science:
- Oncology
- Pain Management
- Neurology
Background:
- Despite current guidelines, 14% of cancer patients experience unrelieved pain or side effects.
- Optimal pain management therapy remains a challenge in oncology care.
Purpose of the Study:
- To evaluate the efficacy of implantable drug delivery systems (IDDS) for managing refractory cancer pain.
- To compare IDDS with comprehensive medical management in a large randomized trial.
Main Methods:
- A randomized trial involving 202 cancer patients with high pain scores (≥7.5) and significant narcotic use.
- Patients received either IDDS or comprehensive medical management.
Main Results:
- IDDS achieved higher clinical success rates (84.5% vs. 70.8%, P=0.05) compared to medical management.
- IDDS significantly reduced pain scores (52% vs. 39%) and drug toxicity (50% vs. 17%).
- IDDS demonstrated improved survival and reduced side effects, even in refractory pain patients.
Conclusions:
- Implantable drug delivery systems represent a superior treatment option for cancer patients with refractory pain.
- IDDS offer better pain control, reduced toxicity, and improved quality of life.
- Evidence from randomized trials supports IDDS as a best treatment for this patient population.